You Are Leaving Avistone's Website
You have selected a link that will take you to a site maintained by a third party. Avistone provides this link as a service to website visitors. Avistone is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click 'Cancel' to return to Avistone's site or 'Continue' to proceed.
2024 WCLC: Vebreltinib Plus PLB1004 In EGFR-Mutated, NSCLC with MET Amplification or MET Overexpression Following EGFR-TKI
Author：Caicu Zhou etc. Time：2024-09-10
Brief Information:
The combination of Vebreltinib and PLB1004 is from Beijing Avistone Biotechnology Co., Ltd.. And the combination is used for treating patients with non-small cell lung cancer who have MET amplification after progression due to EGFR TKI resistance, which is currently undergoing a clinical trial in China. The results of the clinical Phase Ib trial have been invited to give an oral presentation at the 2024 World Conference on Lung Cancer, preliminarily verifying its efficacy and safety.
